As we previously reported, Janssen and Samsung Bioepis jointly filed a stipulation of voluntary dismissal requesting that the District of New Jersey dismiss with prejudice Janssen’s patent infringement claims against Samsung Bioepis based on Samsung Bioepis’s filing of its aBLA for Renflexis® (infliximab-abda). Samsung Bioepis launched Renflexis®, a biosimilar of Remicade®, in July 2017. On November 30, 2017, the Court endorsed the stipulation and ordered the case be dismissed with prejudice. The case is now closed.
The post JANSSEN’S INFLIXIMAB CASE AGAINST SAMSUNG BIOEPIS DISMISSED appeared first on Goodwin Procter BioSimilars Blog.